Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Continues Search For Novel Compounds In Asia, Inking Deal With India's Glenmark For Phase I Biologic

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Continuing with its strategy to aggressively pursue in-licensing of novel R&D from Asia, French drug maker Sanofi signed a deal with India's Glenmark Pharmaceuticals Ltd. for the development and commercialization of GBR 500 - a novel monoclonal antibody for the treatment of Crohn's disease and other inflammatory conditions. The present market size for Crohn's disease is $2-3 billion, executives at Glenmark said, terming the first ever deal for a biological candidate from India as "landmark.

You may also be interested in...

Glenmark’s Pain Drug Fails To Meet Primary Endpoint, Path Of Another Altered By Sanofi

Indian drug maker Glenmark disclosed that Sanofi shelved research on one of its compounds and altered the indication of another biologic for multiple sclerosis treatment.

With Its Third Biologic, India’s Glenmark Claims Success With Anti-OX40 MAb

Glenmark’s Swiss research center is bulking up its pipeline as its third discovery advances to the clinic.

Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)

Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts